New study reveals molecular mechanism in Alzheimer’s disease

A research team at the Institute of Neurosciences of the University of Barcelona (UBneuro) has led a study describing a new molecular mechanism that affects RNA processing and alters the process of protein synthesis in the brains of Alzheimer’s patients.

Daiichi Sankyo and AstraZeneca’s Enhertu snubbed by UK’s NICE for third time – Pharmaceutical Technology

Enhertu is an antibody-drug conjugate (ADC) designed to treat patients with certain types of breast cancer. Credit: Dikushin Dmitry via Shutterstock. The UK’s National Institute

November 20, 2024

NM-6603 by Nucmito for Lung Cancer: Likelihood of Approval

Share this article GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug

January 23, 2024

Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more

Rise and shine, another busy day is on the way. However, this is also shaping up as a beautiful day as well, despite expectations of

July 11, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.